Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ruzaltatug rezetecan

An antibody-drug conjugate (ADC) composed of ruzaltatug, an immunoglobulin G1 (IgG1) human monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3), conjugated, via a cleavable peptide linker, to rezetecan, an exatecan derivative and cytotoxic DNA topoisomerase I inhibitor, with potential antineoplastic activity. Upon administration of ruzaltatug rezetecan, the anti-HER3 antibody moiety targets and binds to HER3 expressed on tumor cells. Upon binding, internalization and linker cleavage, rezetecan targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks, inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER3 ADC SHR-A2009
anti-HER3 antibody-drug conjugate SHR-A2009
Code name:SHR A2009
SHR-A2009
SHRA2009
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search